


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+5.41%
+0.27%
+0.81%
+3.85%
TEVA
Teva Pharma
$24.76
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Investors confidence is positive
Chart
$19.78 (+25.18%)
$18.38 (+34.71%)
$17.01 (+45.56%)
$17.6 (+40.68%)
TEVA has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

TEVA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
TEVA Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
TEVA Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displaySNY
49.25
-0.73%
PFE
25.32
+1.10%
NVS
126.61
-0.55%
MRK
100.80
+3.13%
AZN
91.77
+0.85%
What is TEVA current stock price?
What are TEVA stock strengths?
What is TEVA Risk Level?
What is TEVA market cap and volume?
What is TEVA current Stock IQ?
Should I buy TEVA stock right now?
Is TEVA a Strong Buy right now?
What does a 'Strong Buy' rating mean for TEVA?
What does a 'Strong Sell' rating mean for TEVA?
What factors influence TEVA's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+5.41%
+0.27%
+0.81%
+3.85%
TEVA
Teva Pharma
Current Price
$24.76
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Investors confidence is positive
Linked to TEVA
SNY
49.25
-0.73%
PFE
25.32
+1.10%
NVS
126.61
-0.55%
MRK
100.80
+3.13%
AZN
91.77
+0.85%

Chart
$19.78 (+25.18%)
$18.38 (+34.71%)
$17.01 (+45.56%)
$17.6 (+40.68%)
TEVA Analysts Opinion
TEVA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
TEVA Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
TEVA Street Sentiment is extremely bullish and have positive views on the near-term outlook
TEVA has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels.
TEVA Latest Analysis
Teva to Present at the 8th Annual Evercore Healthcare Conference the Piper Sandler 37th Annual Healthcare Conference and Citis 2025 Global Healthcare Conference in December. TEL AVIV Israel Nov. 21 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis Tevas President and CEO and other members of executive management will present at three upcoming investor conferences in December as follows:
Fri Nov 21, 2025
Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript.
Tue Nov 18, 2025
Teva Pharmaceutical Industries Limited - Depositary Receipt (TEVA) Price Target Increased by 16.51% to 0.06. The average one-year price target for Teva Pharmaceutical Industries Limited - Depositary Receipt (NYSE:TEVA) has been revised to $0.06 / share. This is an increase of 16.51% from the prior estimate of $0.06 dated November 9 2025. The price target is an avera
Mon Nov 17, 2025
Insider Selling: Amir Weiss Unloads $300K Of Teva Pharmaceutical Indus Stock. A substantial insider sell was reported on November 10 by TEVA) based on the recent SEC filing.United States Securities and Exchange Commission on Monday outlined that Weiss executed a sale of 12300 shares of In the Tuesday'.s morning session Teva Pharmaceutical based in Israel is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit p
Tue Nov 11, 2025
Heres How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today. Teva Pharmaceutical Indus (NYSE:TEVA) has outperformed the market over the past 5 years by 6.92% on an annualized basis producing an average annual return of 20.65%. Currently Teva Pharmaceutical Indus has a market capitalization of $27.77 billion.
Mon Nov 10, 2025
Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript.
Mon Nov 10, 2025
JP Morgan Maintains Teva Pharmaceutical Industries Limited - Depositary Receipt (TEVA) Overweight Recommendation. Fintel reports that on November 6 2025 JP Morgan maintained coverage of Teva Pharmaceutical Industries Limited - Depositary Receipt (NYSE:TEVA) with a Overweight recommendation. Analyst Price Forecast Suggests 99.77% Downside
Fri Nov 7, 2025
Teva (TEVA) Hits Multi-Year High as Q3 Strengthens FY25 Profitability Expectations. We recently published 10 Big Names Leading Wall Street Gains. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the best-performing stocks on Wednesday. Teva rallied to a new multi-year high on Wednesday after a stellar performance in the third quarter solidified expectations for a profitable full-year 2025. In intra-day trading Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) [….]
Thu Nov 6, 2025
TEVA Q3 Earnings & Revenues Beat Austedo Sales View Raised Stock Up. Teva stock jumps after third-quarter earnings and revenues top estimates driven by robust Austedo sales as well as United States generics growth.
Thu Nov 6, 2025
Teva (TEVA) Hits All-Time High as Q3 Strengthens FY25 Profitability Expectations. We recently published 10 Big Names Leading Wall Street Gains. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the best-performing stocks on Wednesday. Teva rallied to a new all-time high on Wednesday after a stellar performance in the third quarter solidified expectations for a profitable full-year 2025. In intra-day trading Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) [….]
Thu Nov 6, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
TEVA Stock trends
TEVA Stock performance
TEVA Stock analysis
TEVA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.